ClinicalTrials.gg
RecruitingNCT06123650Updated Oct 3, 2025

Post Stroke Dysphagia: Effect of Adding rTMS to Conventional Therapy on the Prevalence of Pneumonia.

An interventional study of Repetitve transcranial magnetic stimulation and Sham transcranial magnetic stimulation in Stroke, Acute, Dysphagia and Pneumonia, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 49 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-10-03.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
49 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Stroke by Cairo University — 20 open to participants now, 22 under way, none of them phase 3. Stroke · Cairo University.

Planned enrollment
3rd of 38
70 · median 40
Started
2025
with 11 others
No phase
38 of 41
19 open now
Primary completion
2025-12
later than 8 of 21 live
Registered
8th of 41
by date

Among the 41 studies in Stroke by Cairo University, this one is the 3rd largest by planned enrollment of the 38 interventional ones that give a count, is one of 12 that started in 2025, is one of 38 with no phase, reaches primary completion later than 8 of the 21 other live ones, and was the 8th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

20 of the 41 studies in Stroke by Cairo University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 49 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Stroke by Cairo University, or all of them as a file.
02

Study summary

BACKGROUND: Dysphagia is one of the most life-threatening stroke complications. Dysphagic stroke patients are at increased risk of aspiration pneumonia. Pneumonia accounts for at least 10% of post stroke deaths within 30 days of hospitalization after stroke. rTMS is effective in improving post-stroke dysphagia and swallowing coordination after stimulation of the unaffected hemisphere, however it's efficacy on the prevalence of pneumonia has not yet been examined.

Purpose of the study: To determine the effect of adding low frequency repetitive transcranial magnetic stimulation to conventional oropharyngeal physical therapy program on the prevalence of aspiration pneumonia in in patients with post stroke dysphagia.

Read the detailed description

Seventy acute ischemic stroke patients with oropharyngeal dysphagia from both sexes will represent the sample of this study. They will be diagnosed by a neurologist and stroke diagnosis was confirmed by brain MRI and/or CT. They will be selected from the stroke unit El Kasr El Ainy hospital, Cairo university.

Patients will be randomly assigned into two equal groups, the control group (A) and the study group (B). Control group (GA) will be treated using a designed physical therapy intervention for oropharyngeal dysphagia consists of a selected physical therapy rehabilitation program for oropharyngeal muscles in addition to sham repetitive transcranial magnetic stimulation. Study group (GB) will receive low frequency (1 Hz) rTMS to the contra-lesional cerebral hemisphere in addition to the same Oropharyngeal physical therapy program for dysphagia as in group A.

Modified Mann Assessment of Swallowing Ability (MASA) will initially used to confirm dysphagia in acute stroke. The Gugging swallowing screening (GUSS) test will be used to detect aspiration risk. A2DS2 scale will be used to detect stroke associated pneumonia (SAP). Criteria of modified Center for Disease Control and Prevention (CDC) will be used to assess SAP via assessing 4 main measures (body temperature (BT), Total Leukocyte count (TLC), Arterial blood gases (ABG), and Respiratory Rate (RR) .

The whole Intervention will consist of 12 sessions, 3 days /week for 4 consecutive weeks , Total duration of the session (TMS + PT session) will be from 40min to 60 min.

Primary \& secondary outcomes will be assessed at the baseline and immediately after the completion of the whole treatment program.

03

Conditions studied

  • Stroke, Acute
  • Dysphagia
  • Pneumonia

Keywords

  • Stroke
  • Dysphagia
  • Stroke Associated Pneumonia (SAP)
  • Repetitive Transcranial Magnetic Stimulation
  • Contralesional hemisphere
04

Who can participate

Ages eligible
49 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All the patients were diagnosed of stroke oropharyngeal dysphagia by a neurologist. Sever to moderate dysphagia (GUSS 0-14).
  2. Severity of stroke ranged from mild to moderate according to NIHSS score (NIHSS less than or equal 16).
  3. Patients' age ranged from 49 to 65 years old.
  4. Patients had the ability to understand and follow instructions.
  5. Patients were able to sit in upright position.

Exclusion criteria

Exclusion Criteria:

  1. History of previous stroke.
  2. History of any swallowing problem.
  3. History of any head and neck surgery or tumor that causes swallowing dysfunction.
  4. Any lung disease or pneumonia on admission.
  5. Patients with cognitive deficits or disturbed conscious level.
  6. Patients on mechanical ventilator.
  7. Patients with sensory or global aphasia.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Placebo comparator
    Control group (GA)

    Group (A) will receive conventional oral care and oropharyngeal physical therapy program for dysphagia including; Exercise therapy for the oropharyngeal and tongue muscles , in addition to sham transcranial magnetic stimulation on the contralesional cerebral hemisphere.

    Device: Sham transcranial magnetic stimulation

  • Active comparator
    Study group (GB)

    Group (B) will received low frequency (1 Hz) repetitive transcranial magnetic stimulation to the contralesional cerebral hemisphere in addition to the same Oropharyngeal physical therapy program for dysphagia as in group A.

    Device: Repetitve transcranial magnetic stimulation

Interventions

  • DeviceRepetitve transcranial magnetic stimulation

    The Magstim Rapid2 magnetic stimulator system (Model P/N 3576-23-09, Magstim Company, Whitland, UK) was used to deliver rTMS electrical currents via a figure of 8 coil applied to the scalp against the targeted contralesional motor " Hot spot" , at a depth of approximately 1 cm . The inhibitory rTMS will be applied to the intact cerebral hemisphere at 1 Hz with a train of 1200 for 5 consecutive days.

  • DeviceSham transcranial magnetic stimulation

    Repetitive TMS via a sham Magstim coil (identical appearance and noise, but no active stimulation). Identical stimulation schedules as patients in study group.

06

What researchers measure

Primary outcomes

  1. The Gugging swallowing screen (GUSS)

    It's a valid and a reliable bedside screening test to detect dysphagia and aspiration risk. The GUSS has 100% sensitivity. It begins with simple indirect swallow screen then if the total score is reached a direct swallowing test is done. It's composed of three parts: semisolid swallowing trial, liquid swallowing trial and solid swallowing trial. GUSS total score is 20. The score of the preliminary or the direct test is five. If the total score is reached the direct test can be done. Each subitem in the direct test has a score of five points. Each item of them requires the previous item to be completed.

    Time frame: Baseline and immediately after the intervention.

  2. (A2DS2) scale to detect risk of pneumonia

    A2DS2 scale is used to detect stroke associated pneumonia (SAP). Consists of five items of scale which are: age, atrial fibrillation, dysphagia, sex and stroke severity. Total score of A2DS2 is 10. A2DS2 scoring tool: age more than 75 years=1, atrial fibrillation=1, dysphagia=2, male sex=1; stroke severity: is detected by NIHSS score. If NIHSS score is from 0-4=0, 5-15=3, and more than16=5. Patients with score of 6 or more are at high risk of pneumonia.

    Time frame: Baseline and immediately after the intervention.

  3. Microbiological Examination of the sputum

    Sputum specimens collected on sterile sputum containers by patient self-expectoration or aspiration should be checked for quality in a bacteriology laboratory. Quality check typically includes calculating the number of leukocytes (WBC) and buccal squamous epithelial (BSE) cells in the 100× view field .

    Time frame: Baseline and immediately after the intervention

Secondary outcomes

  1. Body Temperature

    According to the diagnostic criteria of stroke associated pneumonia (SAP): follow the modified Center for Disease Control and Prevention (CDC), All patients that were suspected to had pneumonia and their vitals followed the criteria of the CDC . Body temperature was one of the vitals that confirm pneumonia, Fever (\>38°C) with no other recognized cause is one of the diagnostic criteria for pneumonia.

    Time frame: Baseline and immediately after the intervention.

  2. Total Leukocyte Count (TLC)

    According to the diagnostic criteria of SAP follow the modified Center for Disease Control and Prevention (CDC), All patients that were suspected to had pneumonia and their vitals followed the criteria of the CDC. Leukopenia (\<4000 WBC/mm3) or leukocytosis (\>12 000 WBC/mm3). A blood sample is taken from the patient to assess the total leukocyte count.

    Time frame: Baseline and immediately after the intervention.

  3. Arterial Blood Gas (ABG) Test to assess Oxygen Saturation (OS)

    According to the diagnostic criteria of SAP follow the modified Center for Disease Control and Prevention (CDC), All patients that were suspected to had pneumonia and their vitals followed the criteria of the CDC. TLC to assess worsening gas exchange (e.g., O2 desaturation \[e.g., PaO2/FiO2≤240\], increased oxygen requirements\*) by taking a blood sample from the patient.

    Time frame: Baseline and immediately after the intervention.

  4. Respiratory Rate (RR)

    Fast breathing was found to be the most useful sign predicting Stroke associated pneumonia (SAP) for both male and female patients .

    Time frame: Baseline and immediately after the intervention.

Other outcomes

  1. Mann Assessment of Swallowing Ability (MASA)

    Screening tool for identifying eating and swallowing disorders in acute stroke , used to quantify aspiration risk via bedside test * predicting dysphagia and aspiration in stroke * 24 clinical items * General patient examination (alertness, cooperation, auditory comprehension, aphasia, apraxia, and dysarthria) * 5-point to 10-point rating scale * Total score: 200 points * cut off is 177 points * Risk of Dysphagia: No abnormality (≥178), mild dysphagia (168-177), moderate dysphagia (139-167), severe dysphagia (≤138) * Risk of Aspiration: no abnormality (≥170), mild (149-169), moderate (141-148), severe (≤140).

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 9 months is below that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2023
First posted
Nov 9, 2023
StartActual
Mar 22, 2025
Primary completionEst.
Dec 28, 2025
CompletionEst.
Jan 27, 2026
Last update
Oct 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06123650
Lead sponsor
Cairo University
Responsible party
Engy Badreldin Saleh Moustafa, PhD (Lecturer of Physical Therapy for Neurology and Neurosurgery, Cairo University) — Principal investigator
First posted
Nov 9, 2023
Start date
Mar 22, 2025
Primary completion
Dec 28, 2025 (estimated)
Completion
Jan 27, 2026 (estimated)
Last update
Oct 3, 2025

Study contacts

Engy B. Moustafa, PhD
Contact
engybm.saleh@cu.edu.eg
00201099445112
Moshera H. Darwish, PhD
Contact
dr.moshera11@yahoo.com
00201015163617
Engy B. Moustafa, PhD
principal investigator · Faculty of Physical Therapy, Cairo University, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion